Vironex 1 Pot

✔️ Dosage and Administration

Adults and Adolescents (≥16 Years)

Nucleoside Treatment-Naïve Patients with Compensated Liver Disease

• 0.5 mg once daily

Lamivudine-Refractory Patients or Patients with Known Lamivudine/Telbivudine Resistance

• 1 mg once daily

Decompensated Liver Disease

• 1 mg once daily

Pediatric Use

For children aged 2 years and older weighing at least 10 kg, dosing should be determined according to body weight and available formulations.

• Safety and efficacy have not been established in children under 2 years of age.
• Patients aged 16 years and older may receive adult doses.

Renal Impairment

Dose adjustment is required in patients with reduced kidney function.

Standard Dose (0.5 mg Daily)

For Lamivudine-Resistant or Decompensated Liver Disease (1 mg Daily)

• Must be taken on an empty stomach.
• Take at least 2 hours after a meal and 2 hours before the next meal.
• Swallow the tablet whole with water.

Missed Dose

If a dose is missed:

• Take it as soon as remembered.
• If it is almost time for the next scheduled dose, skip the missed dose.
• Do not take a double dose to compensate for a missed dose.

✔️ Drugs Affecting Renal Function

Medicines that:

• Reduce kidney function, or
• Compete for active tubular secretion,

may increase blood concentrations of entecavir or the concomitant medication.

Examples include certain nephrotoxic drugs and medications eliminated primarily through the kidneys.

Patients receiving such combinations should be monitored carefully.

✔️ Side Effects

• Headache
• Dizziness
• Fatigue
• Nausea
• Diarrhea
• Dyspepsia
• Vomiting
• Somnolence
• Insomnia

✔️ Vironex 1 is contraindicated in patients with:

• Known hypersensitivity to Entecavir
• Hypersensitivity to any component of the formulation

✔️ Pregnancy & Lactation

Pregnancy

Available human data remain limited and are insufficient to determine the risk of birth defects, miscarriage, or adverse fetal outcomes.

Entecavir should be used during pregnancy only if the expected benefit outweighs potential risks.

Pregnant patients should discuss treatment options with their physician.

Breastfeeding

It is unknown whether Entecavir passes into human breast milk.

Because of the potential for adverse effects in nursing infants, the benefits of breastfeeding should be weighed against the mother's need for treatment.

✔️ Precautions and Warnings

Lactic Acidosis and Hepatomegaly

Serious cases of:

• Lactic acidosis
• Severe hepatomegaly with steatosis

have been reported with nucleoside analogue therapy, including fatal cases. Patients should be evaluated promptly if symptoms such as unexplained weakness, abdominal pain, rapid breathing, or persistent nausea occur.

Hepatitis B Exacerbation After Discontinuation

Severe acute exacerbations of hepatitis B have been reported after stopping antiviral therapy.

Patients discontinuing Entecavir should undergo:

• Clinical monitoring
• Liver function testing
• HBV DNA monitoring

for several months after treatment cessation.

Renal Monitoring

Because Entecavir is primarily eliminated by the kidneys, renal function should be monitored periodically, especially in:

• Elderly patients
• Patients with renal impairment
• Patients receiving nephrotoxic medications

HIV Coinfection

In patients with untreated HIV infection, Entecavir may contribute to the development of HIV resistance. HIV status should be assessed before initiating therapy.

✔️ Storage:

• Store below 30°C.
• Keep in a cool, dry place.
• Protect from light and moisture.
• Keep out of the reach of children.